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Yoghurt enriched with Lactobacillus acidophilus does not lower
blood lipids in healthy men and women with normal to
borderline high serum cholesterol levels
NM de Roos1*, G Schouten1 and MB Katan1;2
1Division of Human Nutrition and Epidemiology, Wageningen Agricultural University, The Netherlands; and 2The Wageningen Centre
for Food Sciences
Objective: To investigate whether intake of Lactobacillus acidophilus strain L-1 lowers serum cholesterol in
healthy men and women.
Design: Randomised, placebo-controlled parallel trial.
Setting: Subjects were free-living. Blood sampling and distribution of yoghurts were administered at a local
hospital.
Subjects: Seventy-eight adult men and women with cholesterol levels of 3.9±7.8 mmol=L (mean s.d.,
5.4 0.7).
Interventions: Subjects consumed 500 mL of control yoghurt daily for two weeks. They were then randomly
allocated to receive 500 mL per day of control yoghurt or of yoghurt enriched with Lactobacillus acidophilus L-1
for another six weeks. The yoghurts were spiked with a trace of lithium; compliance as assessed by plasma
lithium was excellent.
Results: Energy and nutrient intake was constant, and identical for the two groups. Mean body weight was
stable. Baseline blood lipid concentrations in the control and treatment groups were highly similar. The effect of
consumption of Lactobacillus acidophilus L-1 vs control on total cholesterol was 70.02 mmol=L (95% CI,
70.18±0.15) after three weeks and 0.04 mmol=L (95% CI, 70.12±0.20) after six weeks. Serum LDL and HDL-
cholesterol and triacylglycerol levels were also unaffected.
Conclusions: Yoghurt enriched with Lactobacillus acidophilus L-1 does not lower serum cholesterol in men and
women with normal to borderline high cholesterol levels.
Sponsorship: Dutch Dairy Foundation on Nutrition and Health.
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Introduction
The potential bene®cial effects of the so-called `probiotic'
bacteria has raised much interest (Fuller, 1989; Orrhage et al,
1995; Saxelin, 1997) with cholesterol-lowering as a focus of
research (Agerbñk et al, 1995; Richelsen et al, 1996; Lin et al,
1989; Schaafsma et al, 1998; Mital & Garg, 1995). Commer-
cial products with Lactobacillus acidophilus that claim to
lower serum cholesterol are marketed by several major dairy
companies in Europe (Anonymous, 1996). However, this
claim is mainly based on in vitro and animal studies. Several
Lactobacillus acidophilus strains of human origin are able to
remove cholesterol from culture media during growth in the
presence of bile (Buck & Gilliland, 1994; Gilliland et al,
1985; Walker & Gilliland, 1993). The mechanism of action is
probably that the bacteria deconjugate bile acids which, when
deconjugated, coprecipitate with cholesterol at a pH< 5.5
(Gilliland et al, 1985; Klaver & Van der Meer, 1993; Tahri et
al, 1995). If this also occurs in vivo, such coprecipitation
might increase faecal excretion of bile acids and cholesterol.
It is thought that the liver will compensate for the loss of bile
acids by converting cholesterol into new bile acids. This
conversion of cholesterol into bile acids might lower serum
cholesterol levels.
Evidence for a serum cholesterol lowering effect of
Lactobacillus acidophilus in humans is sparse. Lin et al,
1989 found a cholesterol lowering effect of a mixture of
Lactobacillus acidophilus and Lactobacillus bulgaricus in a
16-week parallel, placebo-controlled pilot trial with 38
subjects, but no effect in a subsequent 15-week double
blind, cross-over trial with 344 subjects (Lin et al, 1989).
Consumption of yoghurt with Lactobacillus acidophilus in
a cross-over study with 30 healthy men resulted in 4.4%
lower mean cholesterol concentrations than consumption of
a placebo (Schaafsma et al, 1998).
We investigated whether Lactobacillus acidophilus low-
ered serum cholesterol in a placebo-controlled, double-
blind study with healthy volunteers. We chose volunteers
with normal to borderline-high serum cholesterol levels
because this is the target group for these yoghurts and
because most dietary components that can lower serum
cholesterol do so also in normocholesterolaemic subjects
(Lu et al, 1997; Pelletier et al, 1995). We chose a treatment
period of six weeks because the same period or shorter was
chosen in previous studies (Agerbñk et al, 1995; Lin et al,
1989; Schaafsma et al, 1998). To our knowledge every
dietary component that lowers cholesterol does so within
six weeks. We chose the maximum dose that could be
given in a yoghurt.
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Subjects and methods
Prior approval for this study was obtained from the Medical
Ethical Committee of the Department of Human Nutrition,
Wageningen Agricultural University. All volunteers gave
their written informed consent. Volunteers who completed
the study received a ®nancial reward.
Subjects
Eligible for the study were healthy men and women
between 18 and 65 y old who were free of heart disease,
diabetes, liver or kidney disease, and did not use any
medications known to affect blood lipid metabolism.
Ninety-nine volunteers were screened and 85 were
enrolled. Volunteers with a serum total cholesterol concen-
tration higher than 8 mmol=L or a triacylglycerol concen-
tration higher than 4 mmol=L were excluded. We made sure
that at least 50% of the enrolled volunteers had serum
cholesterol levels over 5 mmol=L, the cut-off value for mild
hypercholesterolaemia in the Netherlands (Anonymous,
1992). Three subjects dropped out because of vacations,
two because of illness, one because she could not eat all the
yoghurt and one because of gastrointestinal complaints.
The study was completed by 39 subjects in each of the two
test groups.
Study design
After a two-week run-in period, in which the subjects added
500 mL of control yoghurt to their daily diet, subjects were
strati®ed according to sex, age and LDL-cholesterol. Sub-
jects in each stratum were randomly allocated to receive
either control or Lactobacillus acidophilus yoghurt for six
weeks. Venous blood samples were taken after an overnight
fast at the end of the run-in period and at three and six
weeks after the start of the test-period. Blood samples were
taken twice in each week at an interval of 2±4 d, which
amounted to a total of six blood samples during the study.
Yoghurts
The control yoghurt was a non-fat yoghurt with a starter
culture of Streptococcus thermophilus. The test yoghurt
was control yoghurt enriched with Lactobacillus acidophi-
lus L-1. The yoghurt was made once a week (NIZO, the
Netherlands) and was given fresh, not pasteurised. Subjects
were instructed to take 200 mL of the yoghurt directly after
breakfast and 300 mL directly after dinner.
Samples of both yoghurts were analysed on Rogosa
medium every week. Levels of Lactobacillus acidophilus
ranged from 4.86 109 to 2.76 1010 colony forming units
per 500 mL.
Measurements
Blood samples were allowed to clot at room temperature
and were centrifuged for 10 min at 15006 g. Serum
samples were stored at 780C.
Serum lipids were measured or computed as described
previously (Siedel et al, 1983; Warnick et al, 1982;
Sullivan et al, 1985), with an intra-run coef®cient of
variance of 2.6% and an inter-run coef®cient of variance
of 3.8%.
Body weight was measured with subjects clothed but
without shoes. We used a single 24 h recall method to
estimate energy and macronutrient intake in all subjects.
Compliance
Lithium chloride (250 mmol) was added to the yoghurt
(500 mL) as a marker (Sanchez-Castillo et al, 1987).
Toxic effects of lithium below the therapeutic dose have
not been reported (Amdisen, 1977; Lehmann, 1994). The
two serum samples of week three were pooled for lithium
analysis, and so were the two samples of week six.
Serum samples were deproteinised by mixing ®ve parts
with one part of 20% (w=v) trichloroacetic acid. Lithium
concentrations in deproteinised serum samples were mea-
sured by atomic absorption spectrophotometry (Miller et al,
1989).
Subjects recorded missed supplements, illness, and use
of medications in a diary.
Statistical analyses
The two-sample t-test was used to compare changes in the
acidophilus group with changes in the control group.
Results
Each of the two test groups consisted of 11 men and 28
women with a mean age of 40 y and on average normal
body weights and serum cholesterol values (Table 1).
Blood lipid concentrations remained stable in the control
group and were unaffected by consumption of Lactobacillus
acidophilus L-1 (Table 2). The net effect of consumption of
Lactobacillus acidophilus L-1, computed as the difference in
change in blood lipid concentrations between acidophilus
group and control group, was close to zero (Figure 1). We did
not perform separate analyses for men and women because
our study was not designed to do this. Mean changes in blood
lipids, however, were almost identical in men and women.
Twenty-one subjects in the control group and 21 sub-
jects in the acidophilus group had initial serum cholesterol
levels greater than 5.2 mmol=L (200 mg=dL, mean
5.7 0.4 mmol=L), the cut-off value for borderline high
blood cholesterol in the USA (Anonymous, 1993). Lacto-
bacillus acidophilus had no effect on serum cholesterol
levels in this subgroup either: the net effect on total
cholesterol was an elevation of 0.01 mmol=L (95% CI,
70.19±0.21) after three weeks and 0.08 mmol=L (95%
CI, 70.12±0.29) after six weeks. Effects on other blood
lipids were even smaller (data not shown).
Changes in body weight were negligible; the mean
difference in weight change between the acidophilus and
control group was 0.04 kg (95% CI, 70.37±0.44) at week
three and 0.21 kg (95% CI, 70.35±0.78) at week six.
Table 1 Mean ( s.d.) baseline characteristics of 78 subjects who
completed a six-week study into the effect of consumption of
Lactobacillus acidophilus L-1 on serum cholesterol concentrations
Treatment
Characteristic Control Lactobacillus acidophilus L-1
Men=women (number) 11=28 11=28
Age (y) 39.9 8.7 39.8 8.4
Body mass index (kg=m2) 24.2 3.0 23.9 2.6
Total cholesterol (mmol=L) 5.4 0.7 5.3 0.8
Conversion factors: cholesterol, 5mmol=L 193mg=dL.
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Mean intake of total energy, macronutrients, ®bre and
cholesterol as measured by 24 h recall was not different
between the test groups.
Compliance, de®ned as a rise in serum lithium of at least
three times the baseline value, was excellent. Mean serum
lithium levels at three and six weeks were about 6.5-fold
higher than baseline values. Two subjects from the
acidophilus group had an increase from baseline of less
than a factor three: one of them at week three and six, the
other only at week six. Excluding these subjects from the
analysis did not affect the outcome of the study.
Discussion
Lactobacillus acidophilus is the best studied of the `pro-
biotic' cholesterol-lowering bacteria (Lin et al, 1989;
Schaafsma et al, 1998; Harrison & Peat, 1975; Khedkar
et al, 1993; de Rodas et al, 1996). Of all the Lactobacillus
acidophilus-strains the L-1 strain, used in commercial
products in the Netherlands, is thought to be one of
the most effective strains to lower serum cholesterol
(Buck & Gilliland, 1994). Our study, however, shows
that daily consumption of yoghurt enriched with a high
dose of Lactobacillus acidophilus L-1 for a period of six
weeks does not lower blood lipid concentrations in men and
women with normal to borderline high serum cholesterol
levels. The 95% con®dence intervals for the net effect of
the acidophilus yoghurt on serum LDL levels make any
change of more than 0.15 mmol=L (4.7%) unlikely.
The compliance of the subjects, checked by addition of a
trace of lithium to the yoghurts, was excellent. Weight
changes were negligible and background food intake was
the same for the two groups.
Choice of subjects with normal to borderline high serum
cholesterol levels
We do not think that the absence of an effect of the
Lactobacillus acidophilus in our study was due to low
initial cholesterol levels in our subjects. Feeding studies
with fatty acids (Lu et al, 1997; Perez-Jimenez et al, 1995;
Abbey et al, 1994; Cobb & Risch, 1993; Chan et al, 1991),
fat restriction (Lefevre et al, 1997; Jenkins et al, 1997;
Miller et al, 1998; Schaefer et al, 1995), psyllium (Ganji &
Kies, 1996), or phytosterols (Pelletier et al, 1995), have
shown that serum total cholesterol can be reduced in
subjects with comparable or even lower mean serum
cholesterol levels. Also, the subgroup with a mean total
cholesterol level of 5.7 mmol=L (220 mg=dL) did not
respond to Lactobacillus acidophilus either. It is unlikely
that patients with borderline high blood cholesterol will
bene®t from consumption of Lactobacillus acidophilus.
Choice and dosage of probiotic strain
It is possible that the strain we used in our study is not the
most potent strain for cholesterol reduction. However, the
strain used in this present study had the highest ability to
remove cholesterol from a medium in vitro (Buck &
Gilliland, 1994; Gilliland et al, 1985; Walker &
Gilliland, 1993).
The dose we gave, 109±1010 colony-forming units per
day, was up to 1000 times higher than that of previous
studies aimed at cholesterol-lowering (Agerbñk et al, 1995;
Lin et al, 1989; Schaafsma et al, 1998; Harrison & Peat,
1975; Khedkar et al, 1993). It is not possible to incorporate
larger amounts into yoghurts or similar foods.
Length of treatment period
After a run-in period of two weeks we measured serum
cholesterol after three and six weeks of treatment to
measure short-term as well as long-term effects. Although
we cannot exclude an effect of Lactobacillus acidophilus
after a longer treatment period, we are not aware of any
dietary component that has no effect for up to six weeks
and then starts to lower serum cholesterol after more than
six weeks.
The hypothesis for the cholesterol lowering effect of
Lactobacillus acidophilus L-1 is based on its ability to
deconjugate bile acids in vitro. At a pH lower than 5.5
deconjugated bile acids and cholesterol coprecipitate and
are excreted in faeces (Klaver & Van der Meer, 1993).
However, the neutral to alkaline pH of the small intestine
makes precipitation of cholesterol and deconjugated bile
acids in vivo unlikely. Indeed, consumption of a fermented
dairy product containing Lactobacillus acidophilus did not
increase the relative amount of deconjugated bile salts in
faeces of 8 ileostomy patients (Marteau et al, 1995).
Table 2 Blood lipid concentrations after the two-week run-in period and
after three and six weeks of consumption of control yoghurt or yoghurt






Total cholesterol Run-in 5.19 0.74 5.12 0.72
Week 3 5.27 0.74 5.19 0.74
Week 6 5.12 0.69 5.10 0.74
HDL-cholesterol Run-in 1.51 0.40 1.40 0.32
Week 3 1.53 0.44 1.43 0.35
Week 6 1.54 0.41 1.40 0.35
LDL-cholesterol Run-in 3.12 0.80 3.20 0.68
Week 3 3.17 0.82 3.26 0.68
Week 6 3.04 0.80 3.18 0.69
Triacylglycerol Baseline 1.22 0.52 1.13 0.66
Week 3 1.22 0.51 1.10 0.57
Week 6 1.17 0.54 1.11 0.54
Values are means s.d. of 39 subjects in the control group and 39 subjects in
the Lactobacillus acidophilus L-1 group. Conversion factors: Cholesterol,
5mmol=L 193mg=dL; Triacylglycerol 1mmol=L 88.6mg=dL.
Figure 1 Net effects (means and 95% con®dence intervals) on blood
lipid concentrations of daily consumption of yoghurt enriched with
Lactobacillus acidophilus L-1 for six weeks. Net effects were computed
as changes in blood lipid concentrations in the acidophilus group (39
subjects) minus changes in the control group (39 subjects).
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Conclusions
Yoghurt containing Lactobacillus acidophilus strain L-1
did not lower blood lipids in men and women with normal
and borderline high blood cholesterol. Claims to such an
effect would not be justi®ed. More in general, claims made
by commercial producers that probiotic yoghurts lower
serum cholesterol in man should not be based solely on
in vitro and animal studies but should be supported by
proper randomised trials in man.
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